177Lu-9079

177Lu-9079 is a targeted radionuclide therapy (TRT) candidate consisting of a camelid-derived single domain antibody (sdAb), clone 9079, conjugated to the beta-emitting radioisotope Lutetium-177 (177Lu) via a DTPA chelator. It specifically targets human CD20 (huCD20), a cell surface protein. Upon binding to CD20-expressing cells, the drug delivers localized ionizing radiation, primarily high-energy beta particles, which induce double-stranded DNA breaks and generate reactive oxygen species (ROS), leading to cell death. Beyond direct cytotoxicity, 177Lu-9079 has been shown to trigger immunogenic cell death (ICD) and modulate the tumor microenvironment by inducing type I interferon signatures and altering the infiltration of myeloid cells. It is being investigated for the treatment of CD20-positive malignancies, including B-cell lymphomas and potentially other cancers engineered or found to express CD20.

Other names

177Lu-DTPA-9079177Lu-labeled anti-human CD20 sdAb